Premium
P4‐661: REPLICATION TRIAL TO CONFIRM REVERSAL OF COGNITIVE DECLINE WITH BRYOSTATIN FOR ADVANCED ALZHEIMER'S PATIENTS IN THE ABSENCE OF MEMANTINE
Author(s) -
Alkon Daniel L.,
Thompson Richard,
Wei Lee Jen,
Tuchman Alan
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.09.027
Subject(s) - placebo , memantine , medicine , clinical endpoint , bryostatin 1 , donepezil , randomization , cognitive decline , randomized controlled trial , alzheimer's disease , psychology , dementia , disease , alternative medicine , receptor , pathology , activator (genetics)
synaptogenesis and prevent neuronal death, is being evaluated in a double-blind, placebo-controlled confirmatory trial as a treatment for advanced Alzheimer’s disease patients with a dose regimen of 20 μg of bryostatin compared to placebo. 108 subjects were randomized in a 1:1 treatment allocation. Subjects on Namenda (memantine) were excluded. Namenda was previously shown to block sustained cognitive improvement observed in a recently completed Phase II trial. (cf. Farlow et al., 2019 6).